Grade II Meningioma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study (NCT04278118) | Emory University | 2020-02-18 |
| Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma (NCT02847559) | Northwestern University | 2016-08-01 |
Track Grade II Meningioma automatically
Every clearance here is in the API, with alerts when new ones post.